Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for RCDTF and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for RCDTF and 80,000+ other tickers.
See exactly how RCDTF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for RCDTF and 80,000+ other tickers.
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally. It operates through Specialty and Primary Care; and Rare Diseases segments. The company develops Maapliv for maple syrup urine disease; Isturia for endogenous Cushing's syndrome; Cystadrops treatment of the ocular manifestations of cystinosis; Carbaglu for hyperammonemia due to n-acetyl glutamate synthase deficiency; Qarziba for…
Recordati Industria Chimica e Farmaceutica S.p.A. (RICFY) Q1 2026 Earnings Call Transcript
Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF - Get Free Report) and Redhill Biopharma (NASDAQ: RDHL - Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings. Earnings and Valuation This table
Recordati Industria Chimica e Farmaceutica S.p.A. (RICFY) Q4 2025 Earnings Call Transcript
Recordati Industria Chimica e Farmaceutica S.p.A. (RICFY) Presents at 44th Annual J.P.
Recordati Industria Chimica e Farmaceutica S.p.A. (OTCPK:RICFY) Q3 2025 Earnings Call November 12, 2025 8:00 AM EST Company Participants Eugenia Litz - VP & Head of Investor Relations Robert Koremans - CEO & Director Luigi Felice Corte - Group CFO & Executive Director Scott Pescatore - Executive Vice President of Rare Diseases Business Unit Milan Zdravkovic - Executive VP of Research & Development and Chief Medical Officer Conference Call Participants Shan Hama - Jefferies LLC, Research Division Sophia Graeff Buhl Nielsen - JPMorgan Chase & Co, Research Division Isacco Brambilla - Mediobanca - Banca di credito finanziario S.p.A.